New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …

Purpose to investigate the factors affecting survival and toxicity in patients treated with
stereotactic radiosurgery (SRS), with special attention to volumes of brain receiving a …

Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …

Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as
additional conduits for metastatic spread. The identification of growth factor receptor …

Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …

Introduction: This study was performed to determine the incidence rates of resistance factors,
ie, high-level hepatocyte growth factor (HGF) expression, epidermal growth factor receptor …

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor and epidermal growth factor receptor signaling. This randomized, placebo …

The development of personalized medicine with a focus on novel targeted therapies has
supplanted the one-size-fits-all approach to the treatment of many cancers, including non …

The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …